{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T09:14:43Z","timestamp":1783502083659,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":66,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.prp.2023.154543","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T21:57:09Z","timestamp":1684360629000},"page":"154543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases"],"prefix":"10.1016","volume":"247","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2576-6523","authenticated-orcid":false,"given":"Giuseppe","family":"Broggi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Failla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Palicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Zanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Loreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Merolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria","family":"Di Crescenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Ilardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Varricchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Staibano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Caltabiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2023.154543_bib1","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ctrv.2012.01.002","article-title":"Uveal melanoma","volume":"38","author":"Spagnolo","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.prp.2023.154543_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13244-021-01001-w","article-title":"Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part II: treatment indications and complications","volume":"12","author":"Foti","year":"2021","journal-title":"Insights Imaging"},{"key":"10.1016\/j.prp.2023.154543_bib3","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3390\/app9071316","article-title":"Immunohistochemical expression of ABCB5 as a potential prognostic factor in uveal melanoma","volume":"9","author":"Broggi","year":"2019","journal-title":"Appl. Sci."},{"key":"10.1016\/j.prp.2023.154543_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00417-013-2515-0","article-title":"Sufficiency of FNAB aspirates of posterior uveal melanoma for cytologic versus GEP classification in 159 patients, and relative prognostic significance of these classifications","volume":"252","author":"Correa","year":"2014","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.prp.2023.154543_bib5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/cancers14010096","article-title":"Prognostic biomarkers in uveal melanoma: the status quo, recent advances and future directions","volume":"14","author":"Lamas","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2023.154543_bib6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3390\/cancers15030775","article-title":"Genetics and RNA regulation of uveal melanoma","volume":"15","author":"Barbagallo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2023.154543_bib7","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.3390\/app10228081","article-title":"Histopathology and genetic biomarkers of choroidal melanoma","volume":"10","author":"Broggi","year":"2020","journal-title":"Appl. Sci."},{"key":"10.1016\/j.prp.2023.154543_bib8","doi-asserted-by":"crossref","first-page":"59209","DOI":"10.18632\/oncotarget.10962","article-title":"Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas","volume":"7","author":"Field","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2023.154543_bib9","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2023.154543_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.path.2021.01.001","article-title":"PRAME immunohistochemistry as an ancillary test for the assessment of melanocytic lesions","volume":"14","author":"Lezcano","year":"2021","journal-title":"Surg. Pathol. Clin."},{"key":"10.1016\/j.prp.2023.154543_bib11","doi-asserted-by":"crossref","first-page":"10376","DOI":"10.1111\/jcmm.16967","article-title":"Cancer testis antigen PRAME: An anti-cancer target with immunomodulatory potential","volume":"25","author":"Naik","year":"2021","journal-title":"J. Cell Mol. Med"},{"key":"10.1016\/j.prp.2023.154543_bib12","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1097\/PAS.0000000000001944","article-title":"PRAME expression in cancer. A systematic immunohistochemical study of >5800 epithelial and nonepithelial tumors","volume":"46","author":"Kaczorowski","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2023.154543_bib13","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/cup.13818","article-title":"PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features","volume":"47","author":"Raghavan","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.prp.2023.154543_bib14","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00417-019-04335-w","article-title":"Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma","volume":"257","author":"Schefler","year":"2019","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.prp.2023.154543_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12770","article-title":"The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer","volume":"53","author":"Xu","year":"2020","journal-title":"Cell Prolif."},{"key":"10.1016\/j.prp.2023.154543_bib16","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/cancers11070984","article-title":"Cancer testis antigens and immunotherapy: where do we stand in the targeting of PRAME","volume":"11","author":"Al-Khadairi","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2023.154543_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000524051","article-title":"Preferentially expressed antigen in melanoma immunohistochemistry labeling in uveal melanomas","volume":"8","author":"Ahmadian","year":"2022","journal-title":"Ocul. Oncol. Pathol."},{"key":"10.1016\/j.prp.2023.154543_bib18","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.4081\/ejh.2020.3073","article-title":"Defense and protection mechanisms in lung exposed to asbestiform fiber: the role of macrophage migration inhibitory factor and heme oxygenase-1","volume":"64","author":"Loreto","year":"2020","journal-title":"Eur. J. Histochem"},{"key":"10.1016\/j.prp.2023.154543_bib19","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2174\/1566524020666200220130023","article-title":"In vivo immunohistochemical study on MacroH2A.1 in lung and lymph-node tissues exposed to an asbestiform fiber","volume":"20","author":"Loreto","year":"2020","journal-title":"Curr. Mol. Med"},{"key":"10.1016\/j.prp.2023.154543_bib20","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/cncr.29727","article-title":"Uveal melanoma: from diagnosis to treatment and the science in between","volume":"122","author":"Chattopadhyay","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2023.154543_bib21","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/IAE.0b013e31824d09a8","article-title":"Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases","volume":"32","author":"Shields","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.prp.2023.154543_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/eye.2016.275","article-title":"Uveal melanoma: relatively rare but deadly cancer","volume":"31","author":"Kaliki","year":"2017","journal-title":"Eye (Lond. )"},{"key":"10.1016\/j.prp.2023.154543_bib23","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.3390\/app11177874","article-title":"Prognostic value of the immunohistochemical expression of serine and arginine-rich splicing factor 1 (SRSF1) in uveal melanoma: a clinico-pathological and immunohistochemical study on a series of 85 cases","volume":"11","author":"Broggi","year":"2021","journal-title":"Appl. Sci."},{"key":"10.1016\/j.prp.2023.154543_bib24","first-page":"42","article-title":"Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratification of high-risk uveal melanoma patients","volume":"36","author":"Kumar","year":"2023","journal-title":"Hum. Cell"},{"key":"10.1016\/j.prp.2023.154543_bib25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor","volume":"6","author":"Ikeda","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.prp.2023.154543_bib26","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/cup.14267","article-title":"PRAME immunohistochemistry for melanoma diagnosis: A STARD-compliant diagnostic accuracy study","volume":"49","author":"O'Connor","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.prp.2023.154543_bib27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/ICU.0000000000000366","article-title":"New concepts in the molecular understanding of uveal melanoma","volume":"28","author":"Reichstein","year":"2017","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.prp.2023.154543_bib28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/jamaophthalmol.2017.0729","article-title":"PRAME as a potential target for immunotherapy in metastatic uveal melanoma","volume":"135","author":"Gezgin","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.prp.2023.154543_bib29","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3928\/23258160-20220616-01","article-title":"Association of ultrasound features in uveal melanoma with metastatic risk as defined by preferentially expressed antigen in melanoma status","volume":"53","author":"Rusakevich","year":"2022","journal-title":"Ophthalmic Surg. Lasers Imaging Retin."},{"key":"10.1016\/j.prp.2023.154543_bib30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ajo.2018.07.045","article-title":"Gene expression profiling and PRAME status versus tumor-node-metastasis staging for prognostication in uveal melanoma","volume":"195","author":"Cai","year":"2018","journal-title":"Am. J. Ophthalmol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823002431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823002431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:59:19Z","timestamp":1759733959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033823002431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":30,"alternative-id":["S0344033823002431"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2023.154543","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2023.154543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"154543"}}